Landmark lupus approval opens door for next wave of drugs

Nature Reviews Drug Discovery 10, 243-245 (April 2011) | doi:10.1038/nrd3413

The US approval of Human Genome Sciences (HGS) and GlaxoSmithKline's belimumab (Benlysta) on 9 March ended a 50-year drought in the introduction of new lupus drugs. The two firms have blazed a path from mRNA to medicine in 15 years, and analysts are now predicting peak US sales of over US$2 billion annually for the monoclonal antibody (mAb).

link